Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer, according to results from the I-SPY 2 trial presented at the American Association for Cancer Research 2016 Annual Meeting.
Oncology Nurse Advisor